Weekly Tip Sheets (In-Depth Guidance) Dose + Side-Effect Support (Clinically Guided) Labs can be done in-house or with your PCP Why Patients Choose Us for Medical Weight Loss A safety-first, diet-first program with weekly 1:1 supportso you build a lifestyle you can sustain
In addition to these specific symptoms, individuals may experience jaundice (yellowing of the skin and eyes), a result of bile duct obstruction, which prevents bile from being excreted into the intestine and leads to a buildup of bilirubin in the blood
Endurance athletes deplete glutathione faster than the general population due to the oxidative load of heavy training, making daily replenishment directly relevant to recovery and immune resilience

~403 Da (copper complex) Form: Oral capsules Dosage per Capsule: 2mg Capsule Count: 60 capsules per bottle (120mg total) Purity: 99%+ verified by HPLC and mass spectrometry (See COAs) Research Background GHK-Cu has been investigated in research literature across several scientific contexts: Tissue biology research investigations into peptide-copper complex effects on cellular signaling pathways in tissue models Extracellular matrix research studies examining cellular responses involving collagen synthesis pathways and matrix protein regulation in cell culture systems Copper-binding peptide chemistry analytical chemistry research on GHKs selective copper binding properties and the cellular biology of copper homeostasis Cellular signaling pathway research investigations into GHK-Cus interactions with cellular receptor systems and downstream signaling cascades Gene expression research studies examining GHK-Cus effects on cellular gene expression patterns in research models Comparative peptide research analytical studies positioning GHK-Cu alongside other naturally occurring copper-binding peptides in cellular research contexts GHK-Cu is historically significant as one of the most extensively studied naturally occurring copper-binding peptides, originally identified by Pickart et al

A cardiovascular risk-reduction indication was subsequently added following the SELECT trial, reported by Lincoff and colleagues in 2023 [7]
van Galen et al., 2023